^
Association details:
| Biomarker: | HER-2 P780-Y781insGSP |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Vizimpro (dacomitinib) (pan-HER inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors
Excerpt:
The two patients with the exon 20 insertions that had the longest responses had identical amino acid changes (p. P780_Y781insGSP, Table Table1).1). The overall response for the patients with HER2-mutant disease was 12% (95% CI 2% to 30%) and 0% (95% CI 0% to 60%) for the four patients with HER2-amplified tumors
DOI:
10.1093/annonc/mdv186
Trial ID:
